THORNTON JOSEPH CLAY sold $78K of CLOV

THORNTON JOSEPH CLAY (Interim CFO) sold 17,775 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.39 on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · THORNTON JOSEPH CLAY
Published Aug 17, 2026, 9:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The newest fact is the specific sale details (shares, price, total value) and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide new fundamental information.

03

What to watch

The sale size ($78k) is small relative to a public company, and 10b5-1 plans are designed to reduce timing-based inference.

Relevance 2/10Novelty 3/10Timing: filed today, dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction for Clover Health Investments Corp. (DE), reported by Interim CFO Thornton Joseph Clay.

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health insider Thornton Joseph Clay, Interim CFO, sold 17,775 shares at $4.3900 on a 10b5-1 plan filed today.

Expected impact

Likely minimal near-term impact; any reaction would be sentiment-driven rather than a new fundamental catalyst.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, and it does not disclose new operating, financial, or regulatory information.

Market effects

No clear sector read-through because the disclosure is a single-company insider sale without new guidance or events.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with internal caution, so traders may treat it as a mild bearish sentiment input.

Key entities

  • Clover Health Investments Corp. (DE)

    Company whose insider transaction was filed on SEC Form 4.

  • Thornton Joseph Clay

    Interim CFO who sold shares via an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.